Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Most

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Pharmacogenomics and Personalized Medicine|May 28, 2021
Trigger-Specific Remodeling of K<sub>Ca</sub>2 Potassium Channels in Models of Atrial FibrillationAnn-Kathrin Rahm, Dominik Gramlich, Teresa Wieder, et al.
Plos One|November 7, 2025
Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technologyClaire Verkuyl, Ari Belotserkovsky, Thomas Zerbes, et al.
Journal of the American College of Cardiology|August 20, 2011
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytesHenriette Brinks, David Rohde, Mirko Voelkers, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 20, 2005
S100A1 gene therapy preserves in vivo cardiac function after myocardial infarctionSven T Pleger, Andrew Remppis, Beatrix Heidt, et al.
Cardiovascular Diabetology|May 8, 2016
Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathwaySevil Korkmaz-Icöz, Samer Al Said, Tamás Radovits, et al.
The Journal of Biological Chemistry|June 5, 2003
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performancePatrick Most, Andrew Remppis, Sven T Pleger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 27, 2024
CITED4 gene therapy protects against maladaptive cardiac remodeling after ischemia/reperfusion injury in miceCarolin Lerchenmüller, Margaret H Hastings, Charles P Rabolli, et al.
EMBO Molecular Medicine|May 17, 2014
S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4David Rohde, Christoph Schön, Melanie Boerries, et al.
Life Science Alliance|April 11, 2019
m<sup>6</sup>A-mRNA methylation regulates cardiac gene expression and cellular growthVivien Kmietczyk, Eva Riechert, Laura Kalinski, et al.
Circulation. Heart Failure|June 19, 2025
Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic HeartsDorothea Kehr, Janek Salatzki, Birgit Seger, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Pharmacogenomics and Personalized Medicine|May 28, 2021
Trigger-Specific Remodeling of K<sub>Ca</sub>2 Potassium Channels in Models of Atrial FibrillationAnn-Kathrin Rahm, Dominik Gramlich, Teresa Wieder, et al.
Plos One|November 7, 2025
Toward an all-in-one recombinant adeno-associated virus vector for functionally ablating the prion gene using CRISPR-Cas technologyClaire Verkuyl, Ari Belotserkovsky, Thomas Zerbes, et al.
Journal of the American College of Cardiology|August 20, 2011
S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytesHenriette Brinks, David Rohde, Mirko Voelkers, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 20, 2005
S100A1 gene therapy preserves in vivo cardiac function after myocardial infarctionSven T Pleger, Andrew Remppis, Beatrix Heidt, et al.
Cardiovascular Diabetology|May 8, 2016
Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathwaySevil Korkmaz-Icöz, Samer Al Said, Tamás Radovits, et al.
The Journal of Biological Chemistry|June 5, 2003
Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performancePatrick Most, Andrew Remppis, Sven T Pleger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 27, 2024
CITED4 gene therapy protects against maladaptive cardiac remodeling after ischemia/reperfusion injury in miceCarolin Lerchenmüller, Margaret H Hastings, Charles P Rabolli, et al.
EMBO Molecular Medicine|May 17, 2014
S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4David Rohde, Christoph Schön, Melanie Boerries, et al.
Life Science Alliance|April 11, 2019
m<sup>6</sup>A-mRNA methylation regulates cardiac gene expression and cellular growthVivien Kmietczyk, Eva Riechert, Laura Kalinski, et al.
Circulation. Heart Failure|June 19, 2025
Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic HeartsDorothea Kehr, Janek Salatzki, Birgit Seger, et al.
Pageof 11